Sugi Predict

Sugi Predict / Compounds / SCHEMBL6530955

SCHEMBL6530955

SCHEMBL6530955

CC(=CCCCCN)C(N)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PAOX Q6QHF9 3/20 0.41
▸ MAOA P21397 1/20 0.36
▸ MAOB P27338 1/20 0.36
▸ CYP2D6 P10635 1/20 0.34
▸ NFKB1 P19838 1/20 0.34
▸ SLC6A5 Q9Y345 2/20 0.33
▸ BLM P54132 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ PLG P00747 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ SLC6A2 P23975 1/20 0.33
▸ RECQL P46063 1/20 0.33
▸ SLC6A3 Q01959 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ FAAH O00519 2/20 0.32
▸ EP300 Q09472 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3508075 0.98 PAOX (0.45) PAOXMAOAMAOBSLC6A5MEN1
SCHEMBL3675645 0.98 PAOX (0.45) PAOXMAOAMAOBSLC6A5MEN1
SCHEMBL16353966 0.98 PAOX (0.45) PAOXMAOAMAOBSLC6A5MEN1
SCHEMBL16353965 0.98 PAOX (0.45) PAOXMAOAMAOBSLC6A5MEN1
SCHEMBL116656 0.93 PAOX (0.38) PAOXCYP2D6NFKB1BLMNPSR1
SCHEMBL230134 0.93 PAOX (0.38) PAOXCYP2D6NFKB1BLMNPSR1
Hydrochloric Acid SCHEMBL471897 0.91 PAOX (0.37) PAOXCYP2D6NFKB1BLMNPSR1
Hydrochloric Acid SCHEMBL471896 0.91 PAOX (0.37) PAOXCYP2D6NFKB1BLMNPSR1
SCHEMBL11511185 0.91 EP300 (0.37) CYP2D6BLMMEN1ALDH1A1LMNA
SCHEMBL11511188 0.91 EP300 (0.37) CYP2D6BLMMEN1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137844-A1 MEDICAL DEVICE AND METHOD FOR MANUFACTURING THE SAME TERUMO KABUSHIKI KAISHA (JP) 2026-05-21 — — US claimed
EP-4740974-A1 MEDICAL INSTRUMENT AND MANUFACTURING METHOD THEREFOR Terumo Kabushiki Kaisha (JP) 2026-05-13 — — EP claimed
WO-2025260202-A1 AIR PRINTING OF HYDROGELS ALLARTA LIFE SCIENCE INC. (CA) 2025-12-26 — — WO claimed
WO-2025260204-A1 CROSSLINKED HYDROGELS WITH CONTROLLED PERMEABILITY ALLARTA LIFE SCIENCE INC. (CA) 2025-12-26 — — WO claimed
WO-2025260203-A1 CLICK CHEMISTRY POLYMER HYDROGELS ALLARTA LIFE SCIENCE INC. (CA) 2025-12-26 — — WO claimed
WO-2025018283-A1 MEDICAL INSTRUMENT AND MANUFACTURING METHOD THEREFOR テルモ株式会社 2025-01-23 — — WO claimed
WO-2024203010-A1 METHOD FOR PRODUCING MEDICAL INSTRUMENT テルモ株式会社 2024-10-03 — — WO claimed
US-20260137844-A1 MEDICAL DEVICE AND METHOD FOR MANUFACTURING THE SAME TERUMO KABUSHIKI KAISHA (JP) 2026-05-21 — — US disclosed
EP-4740974-A1 MEDICAL INSTRUMENT AND MANUFACTURING METHOD THEREFOR Terumo Kabushiki Kaisha (JP) 2026-05-13 — — EP disclosed
WO-2025260204-A1 CROSSLINKED HYDROGELS WITH CONTROLLED PERMEABILITY ALLARTA LIFE SCIENCE INC. (CA) 2025-12-26 — — WO disclosed
WO-2025260203-A1 CLICK CHEMISTRY POLYMER HYDROGELS ALLARTA LIFE SCIENCE INC. (CA) 2025-12-26 — — WO disclosed
WO-2025260202-A1 AIR PRINTING OF HYDROGELS ALLARTA LIFE SCIENCE INC. (CA) 2025-12-26 — — WO disclosed
WO-2025018283-A1 MEDICAL INSTRUMENT AND MANUFACTURING METHOD THEREFOR テルモ株式会社 2025-01-23 — — WO disclosed
EP-2938641-B1 MOLECULARLY IMPRINTED POLYMERS AND THEIR USE AS ANTIDANDRUFF AGENTS ORÉAL L (FR) 2016-08-24 — — EP disclosed
US-20150342859-A1 MOLECULARLY IMPRINTED POLYMERS AND THEIR USE AS ANTIDANDRUFF AGENTS L'OREAL (FR) 2015-12-03 — — US disclosed
EP-2938641-A1 MOLECULARLY IMPRINTED POLYMERS AND THEIR USE AS ANTIDANDRUFF AGENTS L'Oréal (FR) 2015-11-04 — — EP disclosed
WO-2014102206-A1 MOLECULARLY IMPRINTED POLYMERS AND THEIR USE AS ANTIDANDRUFF AGENTS L'OREAL (FR) 2014-07-03 — — WO disclosed
WO-2005089106-A2 DEGRADABLE NANOPARTICLES MOLECULAR THERAPEUTICS, INC. (US) 2005-09-29 — — WO disclosed
US-20050196343-A1 Polyacrylamide backbone; drug delivery, imaging, diagnosis; easily eliminated by body MOLECULAR THERAPEUTICS, INC. (US) 2005-09-08 — — US disclosed
EP-0277580-A2 Modification of the wet fastness of sulphur dyeings CASSELLA Aktiengesellschaft (DE) 1988-08-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150342859-A1 MOLECULARLY IMPRINTED POLYMERS AND THEIR USE AS ANTIDANDRUFF AGENTS DNMT1, POLR1C, ETF1 PAOX 660/4885MAOA 1282/4885MAOB 1152/4885
US-20260137844-A1 MEDICAL DEVICE AND METHOD FOR MANUFACTURING THE SAME F2, FGB, F9 PAOX 1487/4885MAOA 2857/4885MAOB 2099/4885
US-20050196343-A1 Polyacrylamide backbone; drug delivery, imaging, diagnosis; easily eliminated by body ECPAS, ACTB, SERPINB10 PAOX 250/4885MAOA 1901/4885MAOB 1776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.